evommune inc - EVMN
EVMN
Close Chg Chg %
21.05 2.13 10.12%
Closed Market
23.18
+2.13 (10.12%)
Volume: 477.15K
Last Updated:
Mar 25, 2026, 3:59 PM EDT
Company Overview: evommune inc - EVMN
EVMN Key Data
| Open $21.50 | Day Range 21.24 - 24.14 |
| 52 Week Range N/A - N/A | Market Cap $757.11M |
| Shares Outstanding 36.02M | Public Float 12.28M |
| Beta -13.26 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$2.23 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 337.58K |
EVMN Performance
| 1 Week | -0.86% | ||
| 1 Month | -11.04% | ||
| 3 Months | 34.40% | ||
| 1 Year | N/A | ||
| 5 Years | N/A |
EVMN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About evommune inc - EVMN
Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.
EVMN At a Glance
Evommune, Inc.
1841 Page Mill Road
Palo Alto, California 94304
| Phone | 1-925-247-4487 | Revenue | 13.00M | |
| Industry | Pharmaceuticals: Major | Net Income | -68,870,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 85.714% | |
| Fiscal Year-end | 12 / 2026 | Employees | 48 | |
| View SEC Filings |
EVMN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 41.515 |
| Price to Book Ratio | 2.625 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.926 |
| Enterprise Value to Sales | 30.196 |
| Total Debt to Enterprise Value | 0.005 |
EVMN Efficiency
| Revenue/Employee | 270,833.333 |
| Income Per Employee | -1,434,791.667 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.086 |
EVMN Liquidity
| Current Ratio | 8.57 |
| Quick Ratio | 8.57 |
| Cash Ratio | 8.331 |
EVMN Profitability
| Gross Margin | 89.315 |
| Operating Margin | -623.623 |
| Pretax Margin | -529.769 |
| Net Margin | -529.769 |
| Return on Assets | -45.761 |
| Return on Equity | -224.592 |
| Return on Total Capital | -33.17 |
| Return on Invested Capital | -53.996 |
EVMN Capital Structure
| Total Debt to Total Equity | 1.002 |
| Total Debt to Total Capital | 0.992 |
| Total Debt to Total Assets | 0.916 |
| Long-Term Debt to Equity | 0.716 |
| Long-Term Debt to Total Capital | 0.708 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Evommune Inc - EVMN
Collapse All in section
| All values USD millions. | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
Sales/Revenue
| - | 5.00M | 7.00M | 13.00M | |
Sales Growth
| - | - | +40.00% | +85.71% | - |
Cost of Goods Sold (COGS) incl D&A
| - | 1.00M | 1.29M | 1.39M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 1.00M | 1.29M | 1.39M | |
Depreciation
| - | 1.00M | 1.29M | 1.39M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +28.70% | +7.93% | - |
Gross Income
| - | 4.00M | 5.71M | 11.61M | |
Gross Income Growth
| - | - | +42.83% | +103.24% | - |
Gross Profit Margin
| - | +80.00% | +81.61% | +89.32% |
| 2023 | 2024 | 2025 | 5-year trend | ||
|---|---|---|---|---|---|
SG&A Expense
| - | 41.85M | 75.73M | 92.68M | |
Research & Development
| - | 32.00M | 64.24M | 74.04M | |
Other SG&A
| - | 9.85M | 11.48M | 18.64M | |
SGA Growth
| - | - | +80.95% | +22.39% | - |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | (8.93M) | - |
EBIT after Unusual Expense
| - | (37.85M) | (70.01M) | (72.14M) | |
Non Operating Income/Expense
| - | 3.85M | 3.24M | 3.28M | |
Non-Operating Interest Income
| - | 3.86M | 3.24M | 3.32M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 58.00K | 34.00K | 7.00K | |
Interest Expense Growth
| - | - | -41.38% | -79.41% | - |
Gross Interest Expense
| - | 58.00K | 34.00K | 7.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| - | (34.05M) | (66.81M) | (68.87M) | |
Pretax Income Growth
| - | - | -96.19% | -3.09% | - |
Pretax Margin
| - | -681.06% | -954.40% | -529.77% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| - | (34.05M) | (66.81M) | (68.87M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| - | (34.05M) | (66.81M) | (68.87M) | |
Net Income Growth
| - | - | -96.19% | -3.09% | - |
Net Margin Growth
| - | -681.06% | -954.40% | -529.77% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| - | (34.05M) | (66.81M) | (68.87M) | |
Preferred Dividends
| - | - | - | 1.50M | - |
Net Income Available to Common
| - | (34.05M) | (68.31M) | (68.87M) | |
EPS (Basic)
| - | -1.1322 | -2.2711 | -2.1847 | |
EPS (Basic) Growth
| - | - | -100.59% | +3.80% | - |
Basic Shares Outstanding
| - | 30.08M | 30.08M | 31.52M | |
EPS (Diluted)
| - | -1.1322 | -2.2711 | -2.1847 | |
EPS (Diluted) Growth
| - | - | -100.59% | +3.80% | - |
Diluted Shares Outstanding
| - | 30.08M | 30.08M | 31.52M | |
EBITDA
| - | (36.85M) | (68.73M) | (79.68M) | |
EBITDA Growth
| - | - | -86.50% | -15.94% | - |
EBITDA Margin
| - | -737.00% | -981.80% | -612.94% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 53.125 | |
| Number of Ratings | 10 | Current Quarters Estimate | -0.748 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -2.884 | |
| Last Quarter’s Earnings | -1.43 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -11.22 | Next Fiscal Year Estimate | -3.222 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 9 | 10 | 10 |
| Mean Estimate | -0.75 | -0.68 | -2.88 | -3.22 |
| High Estimates | -0.55 | -0.57 | -2.25 | -2.60 |
| Low Estimate | -0.86 | -0.74 | -3.94 | -4.01 |
| Coefficient of Variance | -12.36 | -8.35 | -15.77 | -11.85 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 8 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Evommune Inc - EVMN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Evommune Inc - EVMN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | EQT Life Sciences Group BV Director | 5,288,313 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $27.88 per share | 147,438,166.44 |
| Dec 12, 2025 | Eugene Andrew Bauer Chief Medical Officer; Director | 270,818 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.84 per share | 4,831,393.12 |
| Dec 12, 2025 | Luis C. Peña President & CEO; Director | 654,683 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.84 per share | 11,679,544.72 |
| Dec 12, 2025 | Janice S. Drew EVP, Operations | 67,794 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.84 per share | 1,209,444.96 |
| Dec 12, 2025 | Gregory S. Moss Chief Business & Legal Officer | 60,835 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.84 per share | 1,085,296.40 |
| Dec 12, 2025 | Kyle Carver Chief Financial Officer | 62,510 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.84 per share | 1,115,178.40 |
| Dec 12, 2025 | Jeegar Patel Chief Scientific Officer | 49,578 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $17.84 per share | 884,471.52 |
| Nov 11, 2025 | Benjamin F. McGraw Director | 37,960 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 11, 2025 | David Eric Cohen Director | 37,960 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |